ArticleScientific reports2023
A diagnostic classification of lung nodules using multiple-scale residual network.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Diagnostic performance of deep learning models in differentiating benign and malignant pulmonary nodules: a systematic review and meta-analysis.Quantitative imaging in medicine and surgery · 2026Article
- An intelligent lung nodule classification model using 3D Trans-DenseUnet++-based lung nodule segmentation.Scientific reports · 2026Article
- The intersection of artificial intelligence and lung nodule research: current applications and future prospects.International journal of surgery (London, England) · 2026Article
- Lung Nodule Malignancy Classification Integrating Deep and Radiomic Features in a Three-Way Attention-Based Fusion Module.Journal of imaging · 2025Article
- Predictive radiomics based ensemble machine learning approach in CT lung nodule diagnosis.Journal of the Egyptian National Cancer Institute · 2025Article
- Integrating Machine Learning in Clinical Practice for Characterizing the Malignancy of Solitary Pulmonary Nodules in PET/CT Screening.Diseases (Basel, Switzerland) · 2024Article
- Radiomics analysis for distinctive identification of COVID-19 pulmonary nodules from other benign and malignant counterparts.Scientific reports · 2024Observational
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Computed tomography (CT) scans have been shown to be an effective way of improving diagnostic efficacy and reducing lung cancer mortality. However, distinguishing benign from malignant nodules in CT imaging remains challenging. This study aims to develop a multiple-scale residual network (MResNet) to automatically and precisely extract the general feature of lung nodules, and classify lung nodules based on deep learning. The MResNet aggregates the advantages of residual units and pyramid pooling module (PPM) to learn key features and extract the general feature for lung nodule classification. Specially, the MResNet uses the ResNet as a backbone network to learn contextual information and discriminate feature representation. Meanwhile, the PPM is used to fuse features under four different scales, including the coarse scale and the fine-grained scale to obtain more general lung features of the CT image. MResNet had an accuracy of 99.12%, a sensitivity of 98.64%, a specificity of 97.87%, a positive predictive value (PPV) of 99.92%, and a negative predictive value (NPV) of 97.87% in the training set. Additionally, its area under the receiver operating characteristic curve (AUC) was 0.9998 (0.99976-0.99991). MResNet's accuracy, sensitivity, specificity, PPV, NPV, and AUC in the testing set were 85.23%, 92.79%, 72.89%, 84.56%, 86.34%, and 0.9275 (0.91662-0.93833), respectively. The developed MResNet performed exceptionally well in estimating the malignancy risk of pulmonary nodules found on CT. The model has the potential to provide reliable and reproducible malignancy risk scores for clinicians and radiologists, thereby optimizing lung cancer screening management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.